ICP-192

DRUG4 trials

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd.

Conditions

Advanced Solid TumorBladder Urothelial CancerIntrahepatic Cholangiocarcinoma (ICC)Solid Tumor

Phase 1

Clinical Study of ICP-192 in Solid Tumors Patients

Beijing InnoCare Pharma Tech Co., Ltd.Solid Tumor

Start: 2018-12-19End: 2024-12-31Target: 56Updated: 2022-07-06

Phase 2

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

RecruitingNCT04492293

Beijing InnoCare Pharma Tech Co., Ltd.Bladder Urothelial Cancer

Start: 2020-05-27End: 2025-06-30Target: 115Updated: 2024-02-26

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Beijing InnoCare Pharma Tech Co., Ltd.Advanced Solid Tumor

Start: 2021-12-15End: 2024-06-30Target: 200Updated: 2023-01-04

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

RecruitingNCT05678270

Beijing InnoCare Pharma Tech Co., Ltd.Intrahepatic Cholangiocarcinoma (ICC)

Start: 2022-11-15End: 2026-12-31Target: 70Updated: 2024-02-07

Related Papers

FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.

2026-08-02

Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.

Journal of Clinical Oncology2023-01-248 citations

Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF/FGFR gene aberrations.

Journal of Clinical Oncology2022-06-011 citations

Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.

Journal of Clinical Oncology2021-05-209 citations